ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2767

Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Evaluation of Modified Minimal Disease Activity upon Elimination of Each Component

Boulos Haraoui1, Proton Rahman2, Louis Bessette3, Philip Baer4, Suneil Kapur5, J. Antonio Avina-Zubieta6, Regan Arendse7, Emmanouil Rampakakis8, Eliofotisti Psaradellis9, Karina Maslova10, Allen J Lehman10, Francois Nantel11, Brendan Osborne12 and Cathy Tkaczyk12, 1University of Montreal, Montreal, QC, Canada, 2Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, 3Rheumatology, CHUL de Quebec, Quebec, QC, Canada, 4Independent Rheumatology Practice, Scarborough, ON, Canada, 5University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, 6Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, 7University of Saskatchewan, Saskatoon, SK, Canada, 8JSS Medical Research, St-Laurent, QC, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Janssen Inc., Toronto, ON, Canada, 1119 Green belt Dr, Janssen Inc., Toronto, ON, Canada, 12Medical Affairs, Janssen Inc., Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords:

Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Minimal disease activity (MDA) is now considered an attainable target in psoriatic arthritis (PsA) reflecting a desired state of comprehensive disease control. MDA is defined as the fulfillment of ≥5 of the following criteria: TJC28≤1, SJC28≤1, PASI≤1, pain (VAS) ≤15 mm, PtGA (VAS) ≤20 mm, HAQ≤0.5, and tender entheseal points ≤1. It is made up of objective and subjective outcomes. The aim of this analysis is to assess the contribution of each criterion in preventing the achievement of MDA at 6 and 12 months.

Methods: BioTRAC is an ongoing, prospective registry of patients initiating treatment for rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA) with infliximab (IFX) or golimumab (GLM). Eligible patients for this analysis included PsA patients treated with IFX or GLM between 2005 and 2010. Modified MDA (mMDA) was evaluated by removing patient-reported outcomes, one criterion at a time, and mMDA achievement was defined as patients who met 4/6 criteria.

Results: A total of 223 PsA patients (51.4% male) were included with a mean (SD) age of 49.8 (11.1) years and disease duration since diagnosis of 5.4 (6.3) years. MDA was achieved by 11.7%, 43.5%, and 44.8% at baseline, at 6 and 12 months of treatment, respectively. At 6 months of treatment the proportion of patients who achieved mMDA upon removing one criterion at a time increased to 54.3% for pain removal, 52.2% for PtGA removal, 50.7% for HAQ removal; while the removal of objective measures did not increase in substantial manner the percentage of patients achieving mMDA: 46.4% for TJC removal, 44.9% for PASI removal, 44.2% for SJC removal, and 44.2% for enthesitis removal. Similar findings were seen at 12 months: the proportion of patients achieving mMDA upon removing HAQ was 58.1%, pain was 57.1%, PtGA was 55.2%, TJC was 50.5%, SJC was 48.6%, PASI was 46.7%, and enthesitis was 45.7%. The highest proportion of mMDA achievement at 6 and 12 months of treatment was observed upon the removal of patient reported pain, PtGA and HAQ.

Conclusion:  The results of the current analysis have shown that the most common limiting factors in achieving MDA in PsA are patient reported outcomes, including PtGA, pain, and HAQ. Elimination of each of these criteria from the MDA formula would result in as many as 13% additional cases of MDA.

Disclosure: B. Haraoui, Janssen Inc., 5; P. Rahman, Janssen Inc., 5; L. Bessette, Janssen Inc., 5; P. Baer, Janssen Inc., 5; S. Kapur, Janssen Pharmaceutica Product, L.P., 5; J. A. Avina-Zubieta, Janssen Inc., 5; R. Arendse, Paid Consultant of Janssen Inc., Canada, 5; E. Rampakakis, employee of JSS Medical Research, 3; E. Psaradellis, employee of JSS Medical Research, 3; K. Maslova, Employee of Janssen Inc., 3; A. J. Lehman, Employee of Janssen Inc., 3; F. Nantel, Employee of Janssen Inc., 3; B. Osborne, Employee of Janssen Inc., 3; C. Tkaczyk, Employee of Janssen Inc., 3.

To cite this abstract in AMA style:

Haraoui B, Rahman P, Bessette L, Baer P, Kapur S, Avina-Zubieta JA, Arendse R, Rampakakis E, Psaradellis E, Maslova K, Lehman AJ, Nantel F, Osborne B, Tkaczyk C. Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Evaluation of Modified Minimal Disease Activity upon Elimination of Each Component [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/minimal-disease-activity-among-psoriatic-arthritis-patients-in-canada-evaluation-of-modified-minimal-disease-activity-upon-elimination-of-each-component/. Accessed .

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/minimal-disease-activity-among-psoriatic-arthritis-patients-in-canada-evaluation-of-modified-minimal-disease-activity-upon-elimination-of-each-component/